{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:18:12Z","timestamp":1791728292859,"version":"4.3.4"},"reference-count":261,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T00:00:00Z","timestamp":1559865600000},"content-version":"am","delay-in-days":491,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01-EY09171-14"],"award-info":[{"award-number":["R01-EY09171-14"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01-EY10659-12"],"award-info":[{"award-number":["R01-EY10659-12"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.addr.2018.01.008","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T21:52:48Z","timestamp":1515793968000},"page":"67-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":222,"special_numbering":"C","title":["Ocular delivery of proteins and peptides: Challenges and novel formulation approaches"],"prefix":"10.1016","volume":"126","author":[{"given":"Abhirup","family":"Mandal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhananjay","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibhuti","family":"Agrahari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang My","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashim K.","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2014","key":"10.1016\/j.addr.2018.01.008_bb0005","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/nbt.3040","article-title":"Biopharmaceutical benchmarks","volume":"32","author":"Walsh","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2018.01.008_bb0010","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1021\/nn4015399","article-title":"Design principles for clinical efficacy of cancer nanomedicine: a look into the basics","volume":"7","author":"Sengupta","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2018.01.008_bb0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrd.2015.12","article-title":"Monoclonal antibody biosimilars","volume":"15","author":"Udpa","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2018.01.008_bb0020","doi-asserted-by":"crossref","DOI":"10.1038\/nrd3790","article-title":"Wet AMD market","volume":"11","author":"Syed","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2018.01.008_bb0025","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jconrel.2014.06.043","article-title":"Ocular delivery of macromolecules","volume":"190","author":"Kim","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.01.008_bb0030","series-title":"The Ophthalmology Market","first-page":"1","author":"S.I.P.M. Limited","year":"2015"},{"key":"10.1016\/j.addr.2018.01.008_bb0035","series-title":"Venture Funding of Therapeutic Innovation: A Comprehensive Look at a Decade of Venture Funding of Drug R&D","first-page":"1","author":"Thomas","year":"2015"},{"key":"10.1016\/j.addr.2018.01.008_bb0040","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nbt0910-917","article-title":"Biopharmaceutical benchmarks 2010","volume":"28","author":"Walsh","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2018.01.008_bb0045","series-title":"Ophthalmology Management","article-title":"FDA rulings advance biosimilar drugs","volume":"20","author":"Helzner","year":"2016"},{"key":"10.1016\/j.addr.2018.01.008_bb0050","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrd4363","article-title":"Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies","volume":"13","author":"Mitragotri","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2018.01.008_bb0055","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/j.ddtec.2009.01.002","article-title":"Intracellular delivery of protein and peptide therapeutics","volume":"5","author":"Torchilin","year":"2008","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.addr.2018.01.008_bb0060","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.addr.2015.08.001","article-title":"Stabilization challenges and formulation strategies associated with oral biologic drug delivery systems","volume":"93","author":"Truong-Le","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2018.01.008_bb0065","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/jamaophthalmol.2016.1284","article-title":"Visual impairment and blindness in adults in the United States: demographic and geographic variations from 2015 to 2050","volume":"134","author":"Varma","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.addr.2018.01.008_bb0070","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrd3745","article-title":"Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma","volume":"11","author":"Zhang","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2018.01.008_bb0075","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.2147\/DDDT.S94188","article-title":"Profile of adalimumab and its potential in the treatment of uveitis","volume":"10","author":"Balevic","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.addr.2018.01.008_bb0080","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2147\/DDDT.S40215","article-title":"Aflibercept in wet AMD: specific role and optimal use","volume":"7","author":"Semeraro","year":"2013","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.addr.2018.01.008_bb0085","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1167\/iovs.12-10260","article-title":"Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach","volume":"54","author":"Xu","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0090","first-page":"263","article-title":"Pegaptanib in the treatment of wet, age-related macular degeneration","volume":"1","author":"Vinores","year":"2006","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2018.01.008_bb0095","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00417-013-2495-0","article-title":"Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes","volume":"252","author":"Moisseiev","year":"2014","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.addr.2018.01.008_bb0100","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2018.01.008_bb0105","first-page":"6","article-title":"Aflibercept approved for macular degeneration","volume":"69","author":"Traynor","year":"2012","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.addr.2018.01.008_bb0110","first-page":"1","article-title":"Aflibercept \u2013 how does it compare with other Anti-VEGF Drugs?","volume":"1","author":"Sharma YR","year":"2014","journal-title":"Austin J. Clin. Ophthalmol."},{"key":"10.1016\/j.addr.2018.01.008_bb0115","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1955","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"Ng","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2018.01.008_bb0120","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.survophthal.2012.01.007","article-title":"Corneal neovascularization: an anti-VEGF therapy review","volume":"57","author":"Chang","year":"2012","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.addr.2018.01.008_bb0125","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4882","article-title":"The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease","volume":"7","author":"Sidman","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2018.01.008_bb0130","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4103\/0974-9233.71588","article-title":"Adalimumab (humira) in ophthalmology: a review of the literature","volume":"17","author":"Neri","year":"2010","journal-title":"Middle East Afr. J. Ophthalmol."},{"key":"10.1016\/j.addr.2018.01.008_bb0135","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.preteyeres.2008.11.005","article-title":"Therapeutic monoclonal antibodies in ophthalmology","volume":"28","author":"Rodrigues","year":"2009","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2018.01.008_bb0140","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/MAJ.0b013e3180318fbc","article-title":"Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation","volume":"27","author":"Theodossiadis","year":"2007","journal-title":"Retina"},{"key":"10.1016\/j.addr.2018.01.008_bb0145","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1517\/13543784.13.10.1275","article-title":"The role of growth factors in the pathogenesis of diabetic retinopathy","volume":"13","author":"Grant","year":"2004","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.addr.2018.01.008_bb0150","first-page":"1586","article-title":"Soluble TNF receptors in vitreoretinal proliferative disease","volume":"42","author":"Limb","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0155","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/sj.eye.6701792","article-title":"Anti-TNF-alpha therapy for uveitis: Behcet and beyond","volume":"19","author":"Murray","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.addr.2018.01.008_bb0160","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2018.01.008_bb0165","doi-asserted-by":"crossref","first-page":"36905","DOI":"10.1038\/srep36905","article-title":"An anti-TNF-alpha antibody mimetic to treat ocular inflammation","volume":"6","author":"Khalili","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2018.01.008_bb0170","doi-asserted-by":"crossref","first-page":"11764","DOI":"10.1038\/srep11764","article-title":"Adalimumab reduces photoreceptor cell death in a mouse model of retinal degeneration","volume":"5","author":"Martinez-Fernandez de la Camara","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2018.01.008_bb0175","doi-asserted-by":"crossref","first-page":"975032","DOI":"10.1155\/2013\/975032","article-title":"Retinal pigment epithelial cells express a functional receptor for glucagon-like peptide-1 (GLP-1)","volume":"2013","author":"Puddu","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.addr.2018.01.008_bb0180","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db15-0443","article-title":"Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes","volume":"65","author":"Hernandez","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2018.01.008_bb0185","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-pharmtox-010611-134654","article-title":"Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy","volume":"55","author":"Pluckthun","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.addr.2018.01.008_bb0190","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ajo.2014.05.037","article-title":"Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I\/II study","volume":"158","author":"Souied","year":"2014","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.addr.2018.01.008_bb0195","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.sjopt.2015.05.005","article-title":"Platelet derived growth factor inhibitors: a potential therapeutic approach for ocular neovascularization","volume":"29","author":"Sadiq","year":"2015","journal-title":"Saudi J. Ophthalmol."},{"key":"10.1016\/j.addr.2018.01.008_bb0200","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nri3459","article-title":"Immunology of age-related macular degeneration","volume":"13","author":"Ambati","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2018.01.008_bb0205","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.drudis.2016.10.015","article-title":"Protein delivery to the back of the eye: barriers, carriers and stability of anti-VEGF proteins","volume":"22","author":"Radhakrishnan","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2018.01.008_bb0210","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jsps.2014.06.004","article-title":"A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives","volume":"24","author":"Muheem","year":"2016","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.addr.2018.01.008_bb0215","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijpharm.2013.02.030","article-title":"Approaches for enhancing oral bioavailability of peptides and proteins","volume":"447","author":"Renukuntla","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2018.01.008_bb0220","first-page":"4093","article-title":"Corneal epithelial tight junctions and their response to lipopolysaccharide challenge","volume":"41","author":"Yi","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0225","doi-asserted-by":"crossref","first-page":"G250","DOI":"10.1152\/ajpgi.2000.279.2.G250","article-title":"Molecular physiology and pathophysiology of tight junctions I. Tight junction structure and function: lessons from mutant animals and proteins","volume":"279","author":"Mitic","year":"2000","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.addr.2018.01.008_bb0230","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/nchem.2629","article-title":"Materials and methods for delivery of biological drugs","volume":"8","author":"Zelikin","year":"2016","journal-title":"Nat. Chem."},{"key":"10.1016\/j.addr.2018.01.008_bb0235","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/138920007779815968","article-title":"Diffusion of macromolecule through retina after experimental branch retinal vein occlusion and estimate of intraretinal barrier","volume":"8","author":"Tao","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.addr.2018.01.008_bb0240","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1167\/iovs.02-1027","article-title":"Human retinal molecular weight exclusion limit and estimate of species variation","volume":"44","author":"Jackson","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0245","first-page":"684","article-title":"Paracellular permeability of corneal and conjunctival epithelia","volume":"30","author":"Huang","year":"1989","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0250","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jconrel.2015.09.065","article-title":"Delivery strategies for treatment of age-related ocular diseases: from a biological understanding to biomaterial solutions","volume":"219","author":"Delplace","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.01.008_bb0255","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000329794","article-title":"Diffusion of protein through the human cornea","volume":"48","author":"Charalel","year":"2012","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.addr.2018.01.008_bb0260","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/jps.2600760802","article-title":"Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea","volume":"76","author":"Ahmed","year":"1987","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0265","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2165\/00003088-199018040-00001","article-title":"Ocular drug delivery. Pharmacokinetic considerations","volume":"18","author":"Schoenwald","year":"1990","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.addr.2018.01.008_bb0270","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/jps.2600670614","article-title":"Relationship between steroid permeability across excised rabbit cornea and octanol-water partition coefficients","volume":"67","author":"Schoenwald","year":"1978","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0275","first-page":"947","article-title":"The dynamics of IgG in the cornea","volume":"18","author":"Allansmith","year":"1979","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.001","article-title":"Corneal structure and transparency","volume":"49","author":"Meek","year":"2015","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2018.01.008_bb0285","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0014-4835(65)80052-5","article-title":"The distribution and movement of serum albumin in the cornea","volume":"4","author":"Maurice","year":"1965","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2018.01.008_bb0290","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0014-4835(71)90143-6","article-title":"Solute permeability of the corneal endothelium and Descemet's membrane","volume":"12","author":"Kim","year":"1971","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2018.01.008_bb0295","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.2042-7158.2010.01153.x","article-title":"In-vitro permeation of bevacizumab through human sclera: effect of iontophoresis application","volume":"62","author":"Pescina","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2018.01.008_bb0300","first-page":"1893","article-title":"Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning","volume":"36","author":"Olsen","year":"1995","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0305","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/0014-4835(77)90136-1","article-title":"Diffusion across the sclera","volume":"25","author":"Maurice","year":"1977","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2018.01.008_bb0310","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1167\/iovs.04-1051","article-title":"Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity","volume":"46","author":"Pitkanen","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0315","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ejpb.2004.10.006","article-title":"Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles","volume":"59","author":"Bilati","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2018.01.008_bb0320","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","article-title":"Challenges and obstacles of ocular pharmacokinetics and drug delivery","volume":"58","author":"Urtti","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2018.01.008_bb0325","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/wnan.1272","article-title":"Controlled ocular drug delivery with nanomicelles, Wiley interdisciplinary reviews","volume":"6","author":"Vaishya","year":"2014","journal-title":"Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.addr.2018.01.008_bb0330","first-page":"1","article-title":"Recent perspectives on the delivery of biologics to back of the eye","author":"Joseph","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2018.01.008_bb0335","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.addr.2006.03.011","article-title":"Formulation and delivery issues for monoclonal antibody therapeutics","volume":"58","author":"Daugherty","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2018.01.008_bb0340","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0022-2836(02)01443-2","article-title":"Effect of dextran on protein stability and conformation attributed to macromolecular crowding","volume":"326","author":"Sasahara","year":"2003","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.addr.2018.01.008_bb0345","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/jps.21190","article-title":"Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways","volume":"97","author":"Kerwin","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0350","doi-asserted-by":"crossref","first-page":"435","DOI":"10.4155\/tde.10.40","article-title":"Recent advances in ophthalmic drug delivery","volume":"1","author":"Kompella","year":"2010","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2018.01.008_bb0355","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/sj.eye.6701669","article-title":"Topically applied antibody fragments penetrate into the back of the rabbit eye","volume":"19","author":"Williams","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.addr.2018.01.008_bb0360","series-title":"Design and Evaluation of Ophthalmic Pharmaceutical Products, Modern Pharmaceutics","author":"Jani","year":"2002"},{"key":"10.1016\/j.addr.2018.01.008_bb0365","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.addr.2006.07.022","article-title":"Industrial perspective in ocular drug delivery","volume":"58","author":"Ali","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2018.01.008_bb0370","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11095-014-1456-6","article-title":"Oxidative stress protection by exogenous delivery of rhHsp70 chaperone to the retinal pigment epithelium (RPE), a possible therapeutic strategy against RPE degeneration","volume":"32","author":"Subrizi","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2018.01.008_bb0375","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nchembio.2006","article-title":"Protein aggregation: a rescue by chaperones","volume":"12","author":"Schymkowitz","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.addr.2018.01.008_bb0380","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2217\/imt.14.34","article-title":"Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies","volume":"6","author":"Wasserman","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1016\/j.addr.2018.01.008_bb0385","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/archopht.116.9.1218","article-title":"Efficacy of hyaluronidase in reducing increases in intraocular pressure related to the use of viscoelastic substances","volume":"116","author":"Harooni","year":"1998","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.addr.2018.01.008_bb0390","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1021\/cr050247k","article-title":"Hyaluronidases: their genomics, structures, and mechanisms of action","volume":"106","author":"Stern","year":"2006","journal-title":"Chem. Rev."},{"key":"10.1016\/j.addr.2018.01.008_bb0395","doi-asserted-by":"crossref","first-page":"6911","DOI":"10.1021\/bi700382g","article-title":"Structure of human hyaluronidase-1, a hyaluronan hydrolyzing enzyme involved in tumor growth and angiogenesis","volume":"46","author":"Chao","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.addr.2018.01.008_bb0400","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1089\/jop.2006.22.362","article-title":"The effect of recombinant human hyaluronidase on dexamethasone penetration into the posterior segment of the eye after sub-Tenon's injection","volume":"22","author":"Kozak","year":"2006","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2018.01.008_bb0405","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1517\/17425247.4.4.427","article-title":"Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration","volume":"4","author":"Frost","year":"2007","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2018.01.008_bb0410","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4593","article-title":"Targeting protein aggregation for the treatment of degenerative diseases","volume":"14","author":"Eisele","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2018.01.008_bb0415","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.molmed.2012.03.005","article-title":"Protein misfolding and aggregation in cataract disease and prospects for prevention","volume":"18","author":"Moreau","year":"2012","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.addr.2018.01.008_bb0420","doi-asserted-by":"crossref","first-page":"10514","DOI":"10.1073\/pnas.1019152108","article-title":"Aggregation of gamma-crystallins associated with human cataracts via domain swapping at the C-terminal beta-strands","volume":"108","author":"Das","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2018.01.008_bb0425","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1586\/17469899.3.1.29","article-title":"Unfolding the therapeutic potential of chemical chaperones for age-related macular degeneration","volume":"3","author":"Sauer","year":"2008","journal-title":"Expert Rev. Ophthalmol."},{"key":"10.1016\/j.addr.2018.01.008_bb0430","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nchembio.2006","article-title":"Protein aggregation: a rescue by chaperones","volume":"12","author":"Schymkowitz","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.addr.2018.01.008_bb0435","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1167\/iovs.10-5392","article-title":"Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications","volume":"51","author":"Edelhauser","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0440","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1167\/iovs.08-1904","article-title":"Drug delivery to posterior intraocular tissues: third annual ARVO\/Pfizer Ophthalmics Research Institute conference","volume":"49","author":"Edelhauser","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0445","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/17425247.3.2.275","article-title":"Ocular drug delivery","volume":"3","author":"Ghate","year":"2006","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2018.01.008_bb0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17425240802650568","article-title":"PEG-modified biopharmaceuticals","volume":"6","author":"Bailon","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2018.01.008_bb0455","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.xphs.2015.11.015","article-title":"PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs","volume":"105","author":"Turecek","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0460","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s13318-013-0126-0","article-title":"Impact of physiochemical properties on pharmacokinetics of protein therapeutics","volume":"38","author":"Swami","year":"2013","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.addr.2018.01.008_bb0465","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10875-010-9468-4","article-title":"Neonatal Fc receptor: from immunity to therapeutics","volume":"30","author":"Kuo","year":"2010","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.addr.2018.01.008_bb0470","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1074\/jbc.M113.537563","article-title":"Structural insights into neonatal Fc receptor-based recycling mechanisms","volume":"289","author":"Oganesyan","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2018.01.008_bb0475","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2015.02.005","article-title":"The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy","volume":"91","author":"Sockolosky","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2018.01.008_bb0480","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2018.01.008_bb0485","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4161\/mabs.2.1.10498","article-title":"A dual-targeting PDGFRbeta\/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo","volume":"2","author":"Mabry","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2018.01.008_bb0490","series-title":"Proceedings of the National Academy of Sciences of the United States of America","article-title":"Supramolecular PEGylation of biopharmaceuticals","author":"Webber","year":"2016"},{"issue":"2006","key":"10.1016\/j.addr.2018.01.008_bb0495","first-page":"e2001","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study","volume":"113","author":"Moshfeghi","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2018.01.008_bb0500","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1167\/iovs.08-2222","article-title":"A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration","volume":"50","author":"Rohrer","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0505","doi-asserted-by":"crossref","first-page":"16939","DOI":"10.1074\/jbc.M808166200","article-title":"Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury","volume":"284","author":"Thurman","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2018.01.008_bb0510","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1167\/iovs.08-3148","article-title":"Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits","volume":"50","author":"Nomoto","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0515","doi-asserted-by":"crossref","first-page":"8718","DOI":"10.1167\/iovs.11-7871","article-title":"Corneal penetration of topical and subconjunctival bevacizumab","volume":"52","author":"Dastjerdi","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0520","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.2337\/db12-0926","article-title":"Topical administration of somatostatin prevents retinal neurodegeneration in experimental diabetes","volume":"62","author":"Hernandez","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2018.01.008_bb0525","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jconrel.2007.11.016","article-title":"Charged nanoparticles delivery to the eye using hydrogel iontophoresis","volume":"126","author":"Eljarrat-Binstock","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.01.008_bb0530","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1007\/s11095-008-9684-2","article-title":"Can ultrasound solve the transport barrier of the neural retina?","volume":"25","author":"Peeters","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2018.01.008_bb0535","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/eye.2011.69","article-title":"Sub-Tenon's anaesthesia: complications and their prevention","volume":"25","author":"Kumar","year":"2011","journal-title":"Eye"},{"key":"10.1016\/j.addr.2018.01.008_bb0540","first-page":"922","article-title":"Sub-Tenon's administration of local anaesthetic: a review of the technique","volume":"91","author":"Mather","year":"2003","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.addr.2018.01.008_bb0545","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.sjopt.2015.06.002","article-title":"Posterior sub-tenon's bevacizumab injection in diabetic macular edema; a pilot study","volume":"29","author":"Falavarjani","year":"2015","journal-title":"Saudi J. Ophthalmol."},{"key":"10.1016\/j.addr.2018.01.008_bb0550","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/ICO.0b013e3181e291a6","article-title":"Deep intrastromal bevacizumab injection for management of corneal stromal vascularization after deep anterior lamellar keratoplasty, a novel technique","volume":"30","author":"Hashemian","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.addr.2018.01.008_bb0555","doi-asserted-by":"crossref","first-page":"7376","DOI":"10.1167\/iovs.14-15257","article-title":"Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization","volume":"55","author":"Kim","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0560","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.jcrs.2014.10.010","article-title":"Intracameral antibiotics: safety, efficacy, and preparation","volume":"40","author":"Braga-Mele","year":"2014","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.addr.2018.01.008_bb0565","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/jamaophthalmol.2016.1351","article-title":"Effectiveness and safety of an intracameral injection of cefuroxime for the prevention of endophthalmitis after cataract surgery with or without perioperative capsular rupture","volume":"134","author":"Daien","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.addr.2018.01.008_bb0570","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/00003226-200210000-00004","article-title":"Intracameral amphotericin B injection in the management of deep keratomycosis","volume":"21","author":"Kuriakose","year":"2002","journal-title":"Cornea"},{"key":"10.1016\/j.addr.2018.01.008_bb0575","doi-asserted-by":"crossref","first-page":"3436415","DOI":"10.1155\/2016\/3436415","article-title":"A combination of intrastromal and intracameral injections of amphotericin B in the treatment of severe fungal keratitis","volume":"2016","author":"Hu","year":"2016","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.addr.2018.01.008_bb0580","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/ICO.0b013e318180e572","article-title":"Effect of intracameral bevacizumab injection on corneal endothelium in rabbits","volume":"27","author":"Park","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.addr.2018.01.008_bb0585","first-page":"3339","article-title":"Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells","volume":"17","author":"Rusovici","year":"2011","journal-title":"Mol. Vis."},{"key":"10.1016\/j.addr.2018.01.008_bb0590","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/IJG.0b013e3181996ed2","article-title":"In vivo corneal endothelial safety of intracameral bevacizumab and effect in neovascular glaucoma combined with Ahmed valve implantation","volume":"18","author":"Shin","year":"2009","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.addr.2018.01.008_bb0595","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3341\/kjo.2009.23.3.188","article-title":"Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma","volume":"23","author":"Lim","year":"2009","journal-title":"Korean J. Ophthalmol."},{"key":"10.1016\/j.addr.2018.01.008_bb0600","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000327364","article-title":"Intracameral injection of bevacizumab for the treatment of neovascular glaucoma","volume":"226","author":"Wolf","year":"2011","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.addr.2018.01.008_bb0605","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ajo.2006.02.045","article-title":"Intracameral bevacizumab for iris rubeosis","volume":"142","author":"Grisanti","year":"2006","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.addr.2018.01.008_bb0610","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10856-015-5556-6","article-title":"Effects of bevacizumab loaded PEG-PCL-PEG hydrogel intracameral application on intraocular pressure after glaucoma filtration surgery","volume":"26","author":"Han","year":"2015","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"10.1016\/j.addr.2018.01.008_bb0615","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1167\/iovs.06-1171","article-title":"Bevacizumab study, penetration of bevacizumab through the retina after intravitreal injection in the monkey","volume":"48","author":"Heiduschka","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0620","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.1167\/iovs.11-7525","article-title":"Effect and distribution of contrast medium after injection into the anterior suprachoroidal space in ex vivo eyes","volume":"52","author":"Seiler","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0625","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1167\/iovs.12-9872","article-title":"Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye","volume":"53","author":"Patel","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0630","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.drudis.2014.10.010","article-title":"The suprachoroidal pathway: a new drug delivery route to the back of the eye","volume":"20","author":"Rai Udo","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2018.01.008_bb0635","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048188","article-title":"Comparison of suprachoroidal drug delivery with subconjunctival and intravitreal routes using noninvasive fluorophotometry","volume":"7","author":"Tyagi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2018.01.008_bb0640","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1167\/iovs.10-6291","article-title":"Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model","volume":"52","author":"Olsen","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0645","article-title":"Suprachoroidal microinjection of bevacizumab is well tolerated in human patients","volume":"54","author":"Morales-Canton","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0650","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","article-title":"Suprachoroidal drug delivery to the back of the eye using hollow microneedles","volume":"28","author":"Patel","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2018.01.008_bb0655","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1023\/A:1015841715384","article-title":"Controlled delivery systems for proteins based on poly(lactic\/glycolic acid) microspheres","volume":"8","author":"Cohen","year":"1991","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2018.01.008_bb0660","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1073\/pnas.90.9.4176","article-title":"Controlled release of polypeptides from polyanhydrides","volume":"90","author":"Ron","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2018.01.008_bb0665","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nrd1576","article-title":"Cyclodextrin-based pharmaceutics: past, present and future","volume":"3","author":"Davis","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2018.01.008_bb0670","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1073\/pnas.0600997103","article-title":"Role of target geometry in phagocytosis","volume":"103","author":"Champion","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2018.01.008_bb0675","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1167\/iovs.01-1156","article-title":"Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres","volume":"44","author":"Carrasquillo","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0680","article-title":"Preparation and characterization of pegaptanib sustained release microsphere formulations for intraocular application","volume":"47","author":"Cook","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0685","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejpb.2003.10.018","article-title":"PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification\/spray-drying as the preparation method: in vitro\/in vivo studies","volume":"57","author":"Gavini","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2018.01.008_bb0690","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1167\/iovs.02-0791","article-title":"Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression","volume":"44","author":"Kompella","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0695","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3109\/02713683.2015.1101140","article-title":"Controlled and extended in vitro release of bioactive anti-vascular endothelial growth factors from a microsphere-hydrogel drug delivery system","volume":"41","author":"Osswald","year":"2016","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.addr.2018.01.008_bb0700","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2010.05.011","article-title":"Issues in long-term protein delivery using biodegradable microparticles","volume":"146","author":"Ye","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.01.008_bb0705","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1023\/B:PHAM.0000019305.79599.a5","article-title":"Poly(lactide\u2011co\u2011glycolide) microsphere formulations of darbepoetin alfa: spray drying is an alternative to encapsulation by spray-freeze drying","volume":"21","author":"Burke","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2018.01.008_bb0710","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijpharm.2015.04.075","article-title":"Reversible hydrophobic ion-paring complex strategy to minimize acylation of octreotide during long-term delivery from PLGA microparticles","volume":"489","author":"Vaishya","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2018.01.008_bb0715","doi-asserted-by":"crossref","DOI":"10.3390\/molecules21081002","article-title":"Stimuli-responsive polymeric systems for controlled protein and peptide delivery: future implications for ocular delivery","volume":"21","author":"Mahlumba","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2018.01.008_bb0720","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ijpharm.2015.11.002","article-title":"Extended release microparticle-in-gel formulation of octreotide: effect of polymer type on acylation of peptide during in vitro release","volume":"496","author":"Vaishya","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2018.01.008_bb0725","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s11095-009-0042-9","article-title":"New techniques for drug delivery to the posterior eye segment","volume":"27","author":"Eljarrat-Binstock","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2018.01.008_bb0730","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1039\/c0sm00088d","article-title":"Temperature controlled encapsulation and release using partially biodegradable thermo-magneto-sensitive self-rolling tubes","volume":"6","author":"Zakharchenko","year":"2010","journal-title":"Soft Matter"},{"key":"10.1016\/j.addr.2018.01.008_bb0735","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.exer.2006.04.014","article-title":"A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres","volume":"83","author":"Li","year":"2006","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2018.01.008_bb0740","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11095-008-9745-6","article-title":"Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina","volume":"26","author":"Kim","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2018.01.008_bb0745","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10384-009-0655-x","article-title":"Subretinal delivery of immunoglobulin G with gold nanoparticles in the rabbit eye","volume":"53","author":"Hayashi","year":"2009","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.addr.2018.01.008_bb0750","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1167\/iovs.10-6229","article-title":"Anti-inflammatory and antiangiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor","volume":"52","author":"Jin","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0755","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.2337\/db08-1327","article-title":"Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage","volume":"58","author":"Park","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2018.01.008_bb0760","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1161\/ATVBAHA.114.304627","article-title":"Nanoparticle-mediated expression of a Wnt pathway inhibitor ameliorates ocular neovascularization","volume":"35","author":"Wang","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2018.01.008_bb0765","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/ATVBAHA.115.305395","article-title":"Wnting out ocular neovascularization: using nanoparticle delivery of very-low density lipoprotein receptor extracellular domain as Wnt pathway inhibitor in the retina","volume":"35","author":"Busik","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2018.01.008_bb0770","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.nano.2016.05.017","article-title":"Physicochemical properties of core-shell type nanoparticles govern their spatiotemporal biodistribution in the eye","volume":"12","author":"Mahaling","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2018.01.008_bb0775","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/02652048.2015.1134685","article-title":"Optimization of novel pentablock copolymer based composite formulation for sustained delivery of peptide\/protein in the treatment of ocular diseases","volume":"33","author":"Patel","year":"2016","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.addr.2018.01.008_bb0780","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1021\/acs.molpharmaceut.5b00828","article-title":"Composite nanoformulation therapeutics for long-term ocular delivery of macromolecules","volume":"13","author":"Agrahari","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2018.01.008_bb0785","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1208\/s12249-014-0196-6","article-title":"Novel pentablock copolymer-based nanoparticulate systems for sustained protein delivery","volume":"16","author":"Patel","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2018.01.008_bb0790","doi-asserted-by":"crossref","first-page":"401747","DOI":"10.1155\/2014\/401747","article-title":"Tailor-made pentablock copolymer based formulation for sustained ocular delivery of protein therapeutics","volume":"2014","author":"Patel","year":"2014","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.addr.2018.01.008_bb0795","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.biomaterials.2016.08.045","article-title":"Inhibition of VEGF mediated corneal neovascularization by anti-angiogenic peptide nanofibers","volume":"107","author":"Senturk","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2018.01.008_bb0800","doi-asserted-by":"crossref","first-page":"10623","DOI":"10.1021\/ja1022267","article-title":"Noninvasive remote-controlled release of drug molecules in vitro using magnetic actuation of mechanized nanoparticles","volume":"132","author":"Thomas","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2018.01.008_bb0805","doi-asserted-by":"crossref","first-page":"11853","DOI":"10.1002\/anie.201204018","article-title":"DNA self-assembly of targeted near-infrared-responsive gold nanoparticles for cancer thermo-chemotherapy","volume":"51","author":"Xiao","year":"2012","journal-title":"Angew. Chem."},{"key":"10.1016\/j.addr.2018.01.008_bb0810","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/IAE.0b013e3181a2f42a","article-title":"Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration","volume":"29","author":"Abrishami","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.addr.2018.01.008_bb0815","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/smll.201303433","article-title":"Topical delivery of Avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes","volume":"10","author":"Davis","year":"2014","journal-title":"Small"},{"key":"10.1016\/j.addr.2018.01.008_bb0820","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijpharm.2006.02.050","article-title":"Cationic liposomes as potential carriers for ocular administration of peptides with anti-herpetic activity","volume":"317","author":"Cortesi","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2018.01.008_bb0825","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s11596-010-0661-8","article-title":"Targeting therapy of choroidal neovascularization by use of polypeptide- and PEDF-loaded immunoliposomes under ultrasound exposure","volume":"30","author":"Li","year":"2010","journal-title":"J. Huazhong Univ. Sci. Technolog. Med. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0830","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0378-5173(02)00080-7","article-title":"Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin","volume":"238","author":"Cavalli","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2018.01.008_bb0835","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejpb.2016.10.006","article-title":"Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: pharmacokinetic studies on rabbits","volume":"109","author":"Chetoni","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2018.01.008_bb0840","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3109\/02652048.2010.517854","article-title":"Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems","volume":"27","author":"Sandri","year":"2010","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.addr.2018.01.008_bb0845","first-page":"1","article-title":"Nanoparticles for the delivery of therapeutic antibodies: dogma or promising strategy?","author":"Sousa","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2018.01.008_bb0850","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3109\/10717544.2010.483257","article-title":"Solid lipid nanoparticles for ocular drug delivery","volume":"17","author":"Seyfoddin","year":"2010","journal-title":"Drug Delivery"},{"key":"10.1016\/j.addr.2018.01.008_bb0855","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1002\/jps.23251","article-title":"Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: improving in vivo ocular bioavailability","volume":"101","author":"Liu","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0860","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1089\/jop.2012.0069","article-title":"Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization, and in vitro evaluation","volume":"29","author":"Hippalgaonkar","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2018.01.008_bb0865","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/jfb6020379","article-title":"Lipid nanoparticles for ocular gene delivery","volume":"6","author":"Wang","year":"2015","journal-title":"J. Funct. Biomater."},{"key":"10.1016\/j.addr.2018.01.008_bb0870","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1021\/nl2036047","article-title":"Remotely activated protein-producing nanoparticles","volume":"12","author":"Schroeder","year":"2012","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2018.01.008_bb0875","doi-asserted-by":"crossref","first-page":"9335","DOI":"10.1021\/nn302148p","article-title":"Lipid-peptide vesicle nanoscale hybrids for triggered drug release by mild hyperthermia in vitro and in vivo","volume":"6","author":"Al-Ahmady","year":"2012","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2018.01.008_bb0880","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1021\/nn304474j","article-title":"A thermoresponsive bubble-generating liposomal system for triggering localized extracellular drug delivery","volume":"7","author":"Chen","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2018.01.008_bb0885","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4103\/0110-5558.76435","article-title":"Niosome: a future of targeted drug delivery systems","volume":"1","author":"Kazi","year":"2010","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"10.1016\/j.addr.2018.01.008_bb0890","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1021\/acs.molpharmaceut.7b00128","article-title":"Topical formulation of self-assembled antiviral prodrug nanomicelles for targeted retinal delivery","volume":"14","author":"Mandal","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2018.01.008_bb0895","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/tvst.4.3.1","article-title":"Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery","volume":"4","author":"Cholkar","year":"2015","journal-title":"Transl. Vision Sci. Technol."},{"key":"10.1016\/j.addr.2018.01.008_bb0900","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.2147\/IJN.S90347","article-title":"Positively charged micelles based on a triblock copolymer demonstrate enhanced corneal penetration","volume":"10","author":"Li","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2018.01.008_bb0905","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2017.01.012","article-title":"Polymeric micelles for ocular drug delivery: from structural frameworks to recent preclinical studies","volume":"248","author":"Mandal","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.01.008_bb0910","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.1016\/j.biomaterials.2009.07.024","article-title":"Synthesis, characterization, and preliminary assessment of anti-Flt1 peptide-hyaluronate conjugate for the treatment of corneal neovascularization","volume":"30","author":"Oh","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2018.01.008_bb0915","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1016\/j.biomaterials.2011.01.003","article-title":"Anti-Flt1 peptide - hyaluronate conjugate for the treatment of retinal neovascularization and diabetic retinopathy","volume":"32","author":"Oh","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2018.01.008_bb0920","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1016\/j.actbio.2012.07.016","article-title":"Flt1 peptide-hyaluronate conjugate micelle-like nanoparticles encapsulating genistein for the treatment of ocular neovascularization","volume":"8","author":"Kim","year":"2012","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2018.01.008_bb0925","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jconrel.2009.05.026","article-title":"Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions\/microbubbles","volume":"138","author":"Rapoport","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.01.008_bb0930","doi-asserted-by":"crossref","first-page":"9268","DOI":"10.1021\/ja1027502","article-title":"Voltage-responsive vesicles based on orthogonal assembly of two homopolymers","volume":"132","author":"Yan","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2018.01.008_bb0935","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jconrel.2008.04.024","article-title":"Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance","volume":"129","author":"Lee","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.01.008_bb0940","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/nbt1171","article-title":"Designing dendrimers for biological applications","volume":"23","author":"Lee","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2018.01.008_bb0945","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1039\/C5BM00532A","article-title":"Stimuli-responsive dendrimers in drug delivery","volume":"4","author":"Wang","year":"2016","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0950","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/jop.2012.0232","article-title":"Dendrimer nanoparticles for ocular drug delivery","volume":"29","author":"Kambhampati","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2018.01.008_bb0955","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1021\/bc900217h","article-title":"RGD dendron bodies; synthetic avidity agents with defined and potentially interchangeable effector sites that can substitute for antibodies","volume":"20","author":"McNerny","year":"2009","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2018.01.008_bb0960","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1021\/bc900228m","article-title":"PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma","volume":"20","author":"Waite","year":"2009","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2018.01.008_bb0965","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2147\/nano.2007.2.1.89","article-title":"Synthesis and characterization of nanoscale dendritic RGD clusters for potential applications in tissue engineering and drug delivery","volume":"2","author":"Yang","year":"2007","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2018.01.008_bb0970","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/jps.20606","article-title":"Protein transduction by lipidic peptide dendrimers","volume":"95","author":"Bayele","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0975","doi-asserted-by":"crossref","first-page":"872","DOI":"10.7150\/thno.9404","article-title":"Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections","volume":"4","author":"Draz","year":"2014","journal-title":"Theranostics"},{"key":"10.1016\/j.addr.2018.01.008_bb0980","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1021\/nn506599f","article-title":"Ocular drug delivery nanowafer with enhanced therapeutic efficacy","volume":"9","author":"Yuan","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2018.01.008_bb0985","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.4155\/tde.15.75","article-title":"Nanostructured materials for ocular delivery: nanodesign for enhanced bioadhesion, transepithelial permeability and sustained delivery","volume":"6","author":"Kim","year":"2015","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2018.01.008_bb0990","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1167\/iovs.16-19074","article-title":"Dexamethasone drug eluting nanowafers control inflammation in alkali-burned corneas associated with dry eye","volume":"57","author":"Bian","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb0995","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2015.07.007","article-title":"Dexamethasone nanowafer as an effective therapy for dry eye disease","volume":"213","author":"Coursey","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.01.008_bb1000","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1021\/acs.molpharmaceut.6b00488","article-title":"Synergistic cysteamine delivery nanowafer as an efficacious treatment modality for corneal cystinosis","volume":"13","author":"Marcano","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2018.01.008_bb1005","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.addr.2005.09.005","article-title":"Intraocular sustained drug delivery using implantable polymeric devices","volume":"57","author":"Yasukawa","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2018.01.008_bb1010","series-title":"Safety of Intravitreal Dexamethasone Implant (Ozurdex): The Safodex Study. Incidence and Risk Factors of Ocular Hypertension, Retina","author":"Malcles","year":"2016"},{"key":"10.1016\/j.addr.2018.01.008_bb1015","first-page":"126463","article-title":"Intravitreal devices for the treatment of vitreous inflammation","volume":"2012","author":"Christoforidis","year":"2012","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.addr.2018.01.008_bb1020","doi-asserted-by":"crossref","first-page":"780634","DOI":"10.1155\/2013\/780634","article-title":"Drug delivery implants in the treatment of vitreous inflammation","volume":"2013","author":"Wang","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.addr.2018.01.008_bb1025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0168-3659(98)00061-3","article-title":"Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy","volume":"55","author":"Zhou","year":"1998","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.01.008_bb1030","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.addr.2006.07.026","article-title":"Intraocular implants for extended drug delivery: therapeutic applications","volume":"58","author":"Bourges","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2018.01.008_bb1035","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1097\/IAE.0b013e31817d8bf2","article-title":"Outcome of fluocinolone acetonide implant (Retisert) reimplantation for chronic noninfectious posterior uveitis","volume":"28","author":"Taban","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.addr.2018.01.008_bb1040","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ophtha.2006.02.021","article-title":"Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study","volume":"113","author":"Jaffe","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2018.01.008_bb1045","first-page":"1186","article-title":"Transscleral delivery of bioactive protein to the choroid and retina","volume":"41","author":"Ambati","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb1050","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.drudis.2013.01.013","article-title":"Injectable implants for the sustained release of protein and peptide drugs","volume":"18","author":"Agarwal","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2018.01.008_bb1055","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1517\/17425247.2012.665367","article-title":"In situ gel systems as \u2018smart\u2019 carriers for sustained ocular drug delivery","volume":"9","author":"Agrawal","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2018.01.008_bb1060","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1021\/mp300716t","article-title":"Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab","volume":"10","author":"Tyagi","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2018.01.008_bb1065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1021\/bm2009558","article-title":"Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel","volume":"13","author":"Wang","year":"2012","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.addr.2018.01.008_bb1070","first-page":"1941","article-title":"Controlled release bevacizumab in thermoresponsive hydrogel found to inhibit angiogenesis","volume":"24","author":"Hu","year":"2014","journal-title":"Biomed. Mater. Eng."},{"key":"10.1016\/j.addr.2018.01.008_bb1075","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijbiomac.2013.05.034","article-title":"Sustained release of Avastin(R) from polysaccharides cross-linked hydrogels for ocular drug delivery","volume":"60","author":"Xu","year":"2013","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.addr.2018.01.008_bb1080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejpb.2014.12.029","article-title":"Silk hydrogels for sustained ocular delivery of anti-vascular endothelial growth factor (anti-VEGF) therapeutics","volume":"95","author":"Lovett","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2018.01.008_bb1085","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1167\/iovs.13-13120","article-title":"Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo","volume":"55","author":"Rauck","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb1090","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jconrel.2004.10.018","article-title":"Cationic TAT peptide transduction domain enters cells by macropinocytosis","volume":"102","author":"Kaplan","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.01.008_bb1095","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1111\/j.1582-4934.2009.00786.x","article-title":"Cell-penetrating peptide TAT-mediated delivery of acidic FGF to retina and protection against ischemia-reperfusion injury in rats","volume":"14","author":"Wang","year":"2010","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.addr.2018.01.008_bb1100","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.visres.2009.08.028","article-title":"Cell penetrating peptide POD mediates delivery of recombinant proteins to retina, cornea and skin","volume":"50","author":"Johnson","year":"2010","journal-title":"Vis. Res."},{"key":"10.1016\/j.addr.2018.01.008_bb1105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/sj.mt.6300324","article-title":"Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea","volume":"16","author":"Johnson","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2018.01.008_bb1110","doi-asserted-by":"crossref","first-page":"11719","DOI":"10.1038\/srep11719","article-title":"Discovery of a non-cationic cell penetrating peptide derived from membrane-interacting human proteins and its potential as a protein delivery carrier","volume":"5","author":"Young Kim","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2018.01.008_bb1115","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.vaccine.2004.09.037","article-title":"Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response","volume":"23","author":"Ho","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2018.01.008_bb1120","doi-asserted-by":"crossref","first-page":"14093","DOI":"10.1073\/pnas.1002713107","article-title":"Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic","volume":"107","author":"Bird","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2018.01.008_bb1125","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jmb.2006.10.088","article-title":"Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10","volume":"365","author":"Cardoso","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.addr.2018.01.008_bb1130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003184","article-title":"Increased functional stability and homogeneity of viral envelope spikes through directed evolution","volume":"9","author":"Leaman","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.addr.2018.01.008_bb1135","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1021\/ol200775h","article-title":"On resin side-chain cyclization of complex peptides using CuAAC","volume":"13","author":"Ingale","year":"2011","journal-title":"Org. Lett."},{"key":"10.1016\/j.addr.2018.01.008_bb1140","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/nsmb.2922","article-title":"Stapled HIV-1 peptides recapitulate antigenic structures and engage broadly neutralizing antibodies","volume":"21","author":"Bird","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.addr.2018.01.008_bb1145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1039\/C4MD00131A","article-title":"Towards understanding cell penetration by stapled peptides","volume":"6","author":"Chu","year":"2015","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.addr.2018.01.008_bb1150","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1089\/jop.2014.0089","article-title":"Peptide therapeutics for treating ocular surface infections","volume":"30","author":"Brandt","year":"2014","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2018.01.008_bb1155","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/nsmb.2922","article-title":"Stapled HIV-1 peptides recapitulate antigenic structures and engage broadly neutralizing antibodies","volume":"21","author":"Bird","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.addr.2018.01.008_bb1160","first-page":"506","article-title":"NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells","volume":"10","author":"Emerich","year":"2008","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.addr.2018.01.008_bb1165","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/11530970-000000000-00000","article-title":"Biodegradable intraocular therapies for retinal disorders: progress to date","volume":"27","author":"Kuno","year":"2010","journal-title":"Drugs Aging"},{"key":"10.1016\/j.addr.2018.01.008_bb1170","doi-asserted-by":"crossref","first-page":"49","DOI":"10.15171\/bi.2016.07","article-title":"Advanced drug delivery and targeting technologies for the ocular diseases","volume":"6","author":"Barar","year":"2016","journal-title":"Bioimpacts"},{"key":"10.1016\/j.addr.2018.01.008_bb1175","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/1874364101206010054","article-title":"Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration","volume":"6","author":"Li","year":"2012","journal-title":"Open Ophthalmol. J."},{"key":"10.1016\/j.addr.2018.01.008_bb1180","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1021\/mp400487f","article-title":"Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab","volume":"10","author":"Yandrapu","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2018.01.008_bb1185","first-page":"653","article-title":"Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits","volume":"8","author":"Ye","year":"2015","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.addr.2018.01.008_bb1190","article-title":"Nanostructured porous silicon dioxide microparticles as an intravitreal injectable drug delivery system for avastin (bevacizumab) lasting six months","volume":"53","author":"Freeman","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb1195","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejps.2013.07.014","article-title":"The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments","volume":"50","author":"Varshochian","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb1200","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1002\/jbm.a.35446","article-title":"Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment","volume":"103","author":"Varshochian","year":"2015","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.addr.2018.01.008_bb1205","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s13346-016-0298-7","article-title":"In vivo and in vitro sustained release of ranibizumab from a nanoporous thin-film device","volume":"6","author":"Lance","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.addr.2018.01.008_bb1210","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1167\/tvst.3.6.5","article-title":"Implantable MicroPump for drug delivery in patients with diabetic macular edema","volume":"3","author":"Humayun","year":"2014","journal-title":"Transl. Vision Sci. Technol."},{"key":"10.1016\/j.addr.2018.01.008_bb1215","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/bjophthalmol-2014-306002","article-title":"One year results of a phase 1 study of the safety and tolerability of combination therapy using sustained release intravitreal triamcinolone acetonide and ranibizumab for subfoveal neovascular AMD","volume":"99","author":"Lim","year":"2015","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.addr.2018.01.008_bb1220","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1167\/tvst.4.2.5","article-title":"Injectable chemically crosslinked hydrogel for the controlled release of bevacizumab in vitreous: a 6-month in vivo study","volume":"4","author":"Yu","year":"2015","journal-title":"Transl. Vision Sci. Technol."},{"key":"10.1016\/j.addr.2018.01.008_bb1225","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejpb.2015.07.024","article-title":"Diels-Alder hydrogels with enhanced stability: First step toward controlled release of bevacizumab","volume":"96","author":"Kirchhof","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2018.01.008_bb1230","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ejpb.2014.07.005","article-title":"Polyethylene glycol (PEG)-Poly(N\u2011isopropylacrylamide) (PNIPAAm) based thermosensitive injectable hydrogels for biomedical applications","volume":"88","author":"Alexander","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2018.01.008_bb1235","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1073\/pnas.1018987108","article-title":"Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration","volume":"108","author":"Zhang","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2018.01.008_bb1240","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/eye.2015.115","article-title":"New and emerging technologies for the treatment of inherited retinal diseases: a horizon scanning review","volume":"29","author":"Smith","year":"2015","journal-title":"Eye"},{"key":"10.1016\/j.addr.2018.01.008_bb1245","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jconrel.2015.04.041","article-title":"Impact insertion of transfer-molded microneedle for localized and minimally invasive ocular drug delivery","volume":"209","author":"Song","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.01.008_bb1250","doi-asserted-by":"crossref","first-page":"7387","DOI":"10.1167\/iovs.14-14651","article-title":"Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles","volume":"55","author":"Kim","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.008_bb1255","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/jphp.12152","article-title":"Microneedle-mediated intrascleral delivery of in situ forming thermoresponsive implants for sustained ocular drug delivery","volume":"66","author":"Thakur","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2018.01.008_bb1260","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nmat1058","article-title":"High-aspect-ratio bulk micromachining of titanium","volume":"3","author":"Aimi","year":"2004","journal-title":"Nat. Mater."},{"key":"10.1016\/j.addr.2018.01.008_bb1265","first-page":"6572","article-title":"Titanium-based, fenestrated, in-plane microneedles for passive ocular drug delivery","volume":"2012","author":"Khandan","year":"2012","journal-title":"Conf. Proc. IEEE Eng. Med. Biol. Soc."},{"key":"10.1016\/j.addr.2018.01.008_bb1270","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/02713680802270945","article-title":"Transcorneal iontophoresis for delivery of ciprofloxacin hydrochloride","volume":"33","author":"Vaka","year":"2008","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.addr.2018.01.008_bb1275","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1097\/01.ico.0000243959.14651.18","article-title":"Iontophoretic treatment of experimental pseudomonas keratitis in rabbit eyes using gentamicin-loaded hydrogels","volume":"25","author":"Frucht-Pery","year":"2006","journal-title":"Cornea"},{"key":"10.1016\/j.addr.2018.01.008_bb1280","first-page":"360","article-title":"Transcorneal and transscleral iontophoresis of the dexamethasone phosphate into the rabbit eye","volume":"63","author":"Raiskup-Wolf","year":"2007","journal-title":"Cesk. Slov. Oftalmol."},{"key":"10.1016\/j.addr.2018.01.008_bb1285","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1089\/jop.2007.0097","article-title":"Methylprednisolone delivery to the back of the eye using hydrogel iontophoresis","volume":"24","author":"Eljarrat-Binstock","year":"2008","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2018.01.008_bb1290","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/02713680701871140","article-title":"In vitro and in vivo evaluation of carboplatin delivery to the eye using hydrogel-iontophoresis","volume":"33","author":"Eljarrat-Binstock","year":"2008","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.addr.2018.01.008_bb1295","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/02713680701528674","article-title":"Methotrexate delivery to the eye using transscleral hydrogel iontophoresis","volume":"32","author":"Eljarrat-Binstock","year":"2007","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.addr.2018.01.008_bb1300","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jconrel.2005.09.049","article-title":"Iontophoresis: a non-invasive ocular drug delivery","volume":"110","author":"Eljarrat-Binstock","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.01.008_bb1305","doi-asserted-by":"crossref","DOI":"10.1063\/1.4942516","article-title":"A flexible device for ocular iontophoretic drug delivery","volume":"10","author":"Zhang","year":"2016","journal-title":"Biomicrofluidics"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X18300085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X18300085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:38:44Z","timestamp":1759207124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X18300085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":261,"alternative-id":["S0169409X18300085"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2018.01.008","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular delivery of proteins and peptides: Challenges and novel formulation approaches","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2018.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}